<DOC>
	<DOCNO>NCT01858558</DOCNO>
	<brief_summary>This research do find alter immune system give Prevnar vaccine , Tadalafil , activate marrow infiltrate lymphocyte ( MILs ) improve outcomes multiple myeloma patient receive standard autologous stem cell transplant .</brief_summary>
	<brief_title>Tadalafil Lenalidomide Maintenance With Without Activated Marrow Infiltrating Lymphocytes ( MILs ) High Risk Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Age 18 80 year old ; Patients active myeloma require systemic treatment ; Newly diagnose patient . Relapsed myeloma patient previously transplant ; Meeting criterion highrisk disease ; Measurable serum and/or urine Mprotein prior induction therapy document available . A positive serum free lite assay acceptable ; ECOG performance status 0 2 ( see Appendix C ) . Meet institutional requirement autologous stem cell transplantation ; The patient must able comprehend sign informed consent ; Patients must &gt; PR last therapy . Diagnosis follow cancer : POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein [ Mprotein ] skin change ) ; Nonsecretory myeloma ( measurable protein Serum Free Lite Assay ) ; Plasma cell leukemia ; Diagnosis amyloidosis ; Failed achieve least partial response ( PR ) late therapy ; Previous hematopoietic stem cell transplantation ; Patients prior relapse disease long never previously transplant ; Known history HIV infection ; Use corticosteroid ( glucocorticoid ) within 21 day bone marrow collection ; Use myelomaspecific therapy within 21 day bone marrow collection ; Infection require treatment antibiotic , antifungal , antiviral agent within seven day registration ; Participation clinical trial within 28 day registration trial , involved investigational drug device ; History malignancy multiple myeloma within five year registration , except adequately treat basal squamous cell skin cancer ; Active autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , systemic lupus erythematosis ) require active systemic treatment . Hypothyroidism without evidence Grave 's disease Hashimoto 's thyroiditis permit . HTLV 1 2 positive ; Known hypersensitivity Prevnar component ; Contraindication phosphodiesterase5 inhibitor ( e.g . currently nitrate ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>